So-Young Q1 Revenue Surges 46% YoY, But Profitability Stays Unproven

What happened

So-Young International reported Q1 2026 revenues of RMB432.8M, a 45.6% increase from RMB297.3M a year ago, driven by continued scaling of its branded aesthetic center network. The top-line growth aligns with the company's pivot from online marketplace to clinic operator, but the press release omitted net income figures, leaving the key question of whether losses are narrowing. In Q3 2025, the company posted a net loss of RMB64.3M and cash reserves had fallen to RMB942.8M from RMB1.25B at year-end 2024. Without evidence of improving profitability or cash stabilization, the revenue beat alone does not validate the operating leverage thesis. Investors should treat this as a positive but incomplete data point until full financials are disclosed.

Implication

The revenue acceleration supports the clinic scaling narrative, but the bear-case risk of persistent losses and cash depletion remains. Until Q1 2026 net income shows narrowing losses and cash draw slows, the stock should be treated as speculative. The WAIT rating is reinforced, with attractive entry near $2.60 if the next quarter confirms operating leverage.

Thesis delta

The 46% revenue beat modestly increases the probability of the base case (services revenue >RMB200M quarterly), but it does not change the core thesis that three proofs are required: consolidated loss narrowing, cash stabilization, and a permanent CFO. Without these, the stock remains a high-risk wait.